Anti-PVRIG antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-12312404-B2
Application number	US-202318448870-A
Country	US
Kind code	B2
Filing date	Aug 11, 2023
Priority date	Feb 19, 2015
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

The present invention is directed to anti-PVRIG antibodies and methods of using same.

First claim

The invention claimed is:

1. A composition comprising an anti-PVRIG antibody, wherein the anti-PVRIG antibody specifically binds to human PVRIG, wherein the antibody comprises a heavy chain and a light chain, and wherein:
a) the heavy chain comprises a heavy chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO: 1434; and
b) the light chain comprises a light chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO:1453.

2. The composition according to claim 1 , wherein the anti-PVRIG antibody specifically binds to human PVRIG with a KD of 10 nM or less.

3. The composition according to claim 1 , wherein the anti-PVRIG antibody activates T-cells and/or NK cells.

4. The composition according to claim 3 , wherein the T cells are cytotoxic T-cells (CTLs).

5. The composition according to claim 3 , wherein the T-cells are CD4+ T-cells or CD8+ T-cells.

6. The composition according to claim 3 , wherein the activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

7. The composition according to claim 1 , wherein the anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein the hinge region optionally comprises one or more mutations.

8. The composition according to claim 7 , wherein the anti-PVRIG antibody comprises the CL region of human kappa 2 light chain.

9. A composition comprising an anti-PVRIG antibody, wherein the anti-PVRIG antibody specifically binds to human PVRIG, wherein the antibody comprises a heavy chain and a light chain, and wherein:
a) the heavy chain comprises a heavy chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO: 1447; and
b) the light chain comprises a light chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO:1462.

10. The composition according to claim 9 , wherein the anti-PVRIG antibody specifically binds to human PVRIG with a K D of 10 nM or less.

11. The composition according to claim 9 , wherein the anti-PVRIG antibody activates T-cells and/or NK cells.

12. The composition according to claim 11 , wherein the T cells are cytotoxic T-cells (CTLs).

13. The composition according to claim 11 , wherein the T-cells are CD4+ T-cells or CD8+ T-cells.

14. The composition according to claim 11 , wherein the activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

15. The composition according to claim 9 , wherein the anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein the hinge region optionally comprises one or more mutations.

16. The composition according to claim 15 , wherein the anti-PVRIG antibody comprises the CL region of human kappa 2 light chain.

Assignees

• Compugen Ltd

Inventors

• White Mark
• Kumar Sandeep
• Chan Christopher
• Liang Spencer
• Stapleton Lance
• Drake Andrew W
• Gozlan Yosi
• Vaknin Ilan
• Sameah-Greenwald Shirley
• Dassa Liat
• Tiran Zohar
• Cojocaru Gad S
• Presta Leonard
• Theolis Richard

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/53

  Hinge · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title